Wedbush Issues Optimistic Estimate for NBIX Earnings

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) – Research analysts at Wedbush lifted their Q1 2025 earnings estimates for Neurocrine Biosciences in a research report issued on Monday, December 23rd. Wedbush analyst L. Chico now forecasts that the company will post earnings of $1.52 per share for the quarter, up from their prior forecast of $1.49. Wedbush currently has a “Outperform” rating and a $148.00 target price on the stock. The consensus estimate for Neurocrine Biosciences’ current full-year earnings is $3.94 per share. Wedbush also issued estimates for Neurocrine Biosciences’ Q2 2025 earnings at $1.82 EPS, Q3 2025 earnings at $1.90 EPS, Q4 2025 earnings at $2.46 EPS, FY2025 earnings at $7.71 EPS and FY2026 earnings at $10.87 EPS.

Other analysts also recently issued reports about the stock. William Blair reissued an “outperform” rating on shares of Neurocrine Biosciences in a report on Monday, December 16th. Raymond James reissued an “outperform” rating and set a $155.00 target price on shares of Neurocrine Biosciences in a research note on Thursday, October 10th. Cantor Fitzgerald restated an “overweight” rating and issued a $155.00 price target on shares of Neurocrine Biosciences in a research note on Monday, September 16th. HC Wainwright reaffirmed a “buy” rating and issued a $190.00 price target on shares of Neurocrine Biosciences in a report on Monday, December 16th. Finally, Barclays raised their price objective on Neurocrine Biosciences from $160.00 to $165.00 and gave the company an “overweight” rating in a report on Monday. Five equities research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Neurocrine Biosciences has a consensus rating of “Moderate Buy” and an average target price of $166.29.

Neurocrine Biosciences Price Performance

NASDAQ NBIX opened at $136.53 on Tuesday. The company has a fifty day moving average of $124.40 and a 200 day moving average of $130.59. The company has a market capitalization of $13.82 billion, a PE ratio of 36.60 and a beta of 0.34. Neurocrine Biosciences has a 1 year low of $110.95 and a 1 year high of $157.98.

Insiders Place Their Bets

In other Neurocrine Biosciences news, insider Ingrid Delaet sold 1,091 shares of the stock in a transaction on Tuesday, December 17th. The stock was sold at an average price of $135.00, for a total value of $147,285.00. Following the completion of the transaction, the insider now owns 2,507 shares in the company, valued at approximately $338,445. This represents a 30.32 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Jude Onyia sold 2,331 shares of the business’s stock in a transaction on Friday, November 29th. The stock was sold at an average price of $126.29, for a total transaction of $294,381.99. Following the sale, the insider now owns 15,449 shares in the company, valued at $1,951,054.21. The trade was a 13.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.30% of the stock is owned by insiders.

Institutional Investors Weigh In On Neurocrine Biosciences

A number of institutional investors and hedge funds have recently modified their holdings of the company. Ashton Thomas Private Wealth LLC purchased a new position in Neurocrine Biosciences during the 2nd quarter valued at about $28,000. Innealta Capital LLC acquired a new stake in shares of Neurocrine Biosciences in the second quarter valued at approximately $30,000. Blue Trust Inc. increased its stake in shares of Neurocrine Biosciences by 171.9% during the 3rd quarter. Blue Trust Inc. now owns 348 shares of the company’s stock worth $40,000 after purchasing an additional 220 shares in the last quarter. Plato Investment Management Ltd raised its position in shares of Neurocrine Biosciences by 44.1% during the 2nd quarter. Plato Investment Management Ltd now owns 425 shares of the company’s stock worth $59,000 after purchasing an additional 130 shares during the last quarter. Finally, Truvestments Capital LLC purchased a new stake in Neurocrine Biosciences in the 3rd quarter valued at approximately $63,000. Institutional investors and hedge funds own 92.59% of the company’s stock.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.